|Bid||19.50 x 900|
|Ask||27.49 x 1000|
|Day's range||24.39 - 25.27|
|52-week range||12.06 - 31.28|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||N/A|
|Earnings date||04 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||28.00|
AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
AnaptysBio (ANAB) reports positive top-line data from an interim analysis of its phase II GALLOP study on imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis.
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have...